Bone regenerative medicine: metatarsus defects in sheep to evaluate new therapeutic strategies for human long bone defect. A systematic review.


Journal

Injury
ISSN: 1879-0267
Titre abrégé: Injury
Pays: Netherlands
ID NLM: 0226040

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 19 11 2019
revised: 01 04 2020
accepted: 08 04 2020
pubmed: 21 5 2020
medline: 19 3 2021
entrez: 21 5 2020
Statut: ppublish

Résumé

Large bone defects in long bone are not able to repair themselves and require grafts. Although autograft is the gold standard, it is associated with some disadvantages. Consequently, the application of tissue engineering (TE) techniques help with the use of allogenic biological and artificial scaffolds, cells and growth factors (GFs). Following 3Rs and in vitro testing strategies, animal models are required in preclinical in vivo studies to evaluate the therapeutic effects of the most promising TE techniques. A systematic review was performed from 2000 to 2019 to evaluate bone regeneration sheep metatarsus defects. Eleven in vivo studies on sheep metatarsus defect were retrieved. The mid-diaphysis of metatarsus was the region most employed to perform critical size defects. Natural, synthetic and hybrid scaffolds were implanted, combined with bone marrow mesenchymal stem cells (BMSCs), GFs such as osteogenic protein 1 (OP1) and platelet rich plasma (PRP). The maximum follow-up period was 4 and 6 months in which radiography, histology, histomorphometry, computed tomography (CT) and biomechanics were performed to evaluate the healing status. the sheep metatarsus defect model seems to be a suitable environment with a good marriage of biological and biomechanical properties. Defects of 3 cm are treated with natural scaffolds (homologous graft or allografts), those of 2.5 cm with natural, synthetic or composite scaffolds, while little defects (0.5 × 0.5 cm) with composite scaffolds. No difference in results is found regardless of the defect size.

Identifiants

pubmed: 32430197
pii: S0020-1383(20)30341-7
doi: 10.1016/j.injury.2020.04.010
pii:
doi:

Substances chimiques

Bone Morphogenetic Protein 7 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1457-1467

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Francesca Veronesi (F)

Laboratory of Preclinical and Surgical Studies, IRCCS-Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136 Bologna, Italy. Electronic address: francesca.veronesi@ior.it.

Lucia Martini (L)

Laboratory of Preclinical and Surgical Studies, IRCCS-Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136 Bologna, Italy. Electronic address: lucia.martini@ior.it.

Gianluca Giavaresi (G)

Laboratory of Preclinical and Surgical Studies, IRCCS-Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136 Bologna, Italy. Electronic address: gianluca.giavaresi@ior.it.

Milena Fini (M)

Laboratory of Preclinical and Surgical Studies, IRCCS-Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136 Bologna, Italy. Electronic address: milena.fini@ior.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH